Introduction {#onco12104-sec-0001}
============

Within the U.S., an estimated 224,390 new cases of lung cancer and 158,080 related deaths were expected in 2016, making lung cancer the leading cause of cancer‐related deaths \[[1](#onco12104-bib-0001){ref-type="ref"}\]. The majority (83%) of lung cancers are classified as non‐small cell lung cancer (NSCLC) \[[1](#onco12104-bib-0001){ref-type="ref"}\], and treatment of NSCLC in the absence of a targetable mutation typically entails surgery, radiation therapy, and platinum‐based chemotherapy, used either alone or in combination depending on disease status \[[2](#onco12104-bib-0002){ref-type="ref"}\]. Several chemotherapeutic drugs have been approved by the U.S. Food and Drug Administration (FDA) for first‐line treatment of NSCLC, including cisplatin, vinorelbine, paclitaxel, gemcitabine, pemetrexed, and docetaxel (also approved for second‐line use) \[[3](#onco12104-bib-0003){ref-type="ref"}\], \[[4](#onco12104-bib-0004){ref-type="ref"}\].

With the advent of molecular testing, which is now standard for treatment of adenocarcinomas, targeted therapies have been implemented into the treatment regimen for NSCLC, with several agents approved by the FDA based on efficacy demonstrated in clinical trials in specific NSCLC patient populations \[[2](#onco12104-bib-0002){ref-type="ref"}\]. To date, the majority of FDA‐approved drugs for NSCLC, including bevacizumab and erlotinib, have shown significant improvement in overall survival (OS) in clinical trials \[[5](#onco12104-bib-0005){ref-type="ref"}\]. However, FDA guidelines have recently stated that substantial and robust differences in time to progression or progression‐free survival (PFS), which are endpoints commonly used in clinical trials as surrogates for OS, can also be used to support accelerated FDA approval of investigational agents \[[5](#onco12104-bib-0005){ref-type="ref"}\]. In addition to the magnitude of the effect, the FDA has recommended examination of the risk‐benefit profile of a drug in order for PFS to be considered as the primary endpoint in support of its approval. Unlike earlier trials that evaluated targeted agents for NSCLC, more recent studies have established PFS or objective response as the primary endpoint \[[6](#onco12104-bib-0006){ref-type="ref"}\], \[[7](#onco12104-bib-0007){ref-type="ref"}\], \[[8](#onco12104-bib-0008){ref-type="ref"}\], \[[9](#onco12104-bib-0009){ref-type="ref"}\], \[[10](#onco12104-bib-0010){ref-type="ref"}\], \[[11](#onco12104-bib-0011){ref-type="ref"}\]. Because clinical trials have to be designed in order to ultimately ensure regulatory approval of the investigational agent, selection of the appropriate endpoint prior to the start of the study is essential. This review will provide an overview of the study designs of historical and recent clinical trials for approved agents in NSCLC and will focus on the validity of alternative endpoints for such trials.

Materials and Methods {#onco12104-sec-0002}
=====================

Published clinical trials supporting FDA approval of investigational agents for NSCLC treatment have been included in this review (Table [1](#onco12104-tbl-0001){ref-type="table"}). For the correlation analysis of clinical trial endpoints (Table [2](#onco12104-tbl-0002){ref-type="table"}), published randomized controlled trials that demonstrated significant improvements in the indicated endpoints and led to FDA approval for the listed chemotherapeutic, targeted, and immunotherapeutic agents were included.

###### Study designs of clinical trials for approved agents for NSCLC[a](#onco12104-note-0002){ref-type="fn"}

![](onco12104-tbl-0001){#nlm-graphic-1}

Only targeted and immunotherapeutic agents have been summarized in this table.

Independent review.

Abbreviations: AE, adverse event; ALK, anaplastic lymphoma kinase; CNS, central nervous system; DoR, duration of response; EGFR, epidermal growth factor receptor; HRQoL, health‐related quality of life; ITT, intention‐to‐treat; MTD, maximum tolerated dose; NR, not reported; NSCLC, non‐small cell lung cancer; OS, overall survival; PD‐L1, programmed death‐ligand 1; PFS, progression‐free survival; PK, pharmacokinetics; PRO, patient‐reported outcome; QoL, quality of life; TKI, tyrosine kinase inhibitor; TTF, time to treatment failure; TTP, time to progression.

###### Correlative analysis of clinical trial endpoints supporting approval of investigational agents for NSCLC
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Abbreviations: BSC, best supportive care; NSCLC, non‐small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival.

Clinical Trial Designs of Approved Targeted Agents for NSCLC {#onco12104-sec-0003}
============================================================

Primary and secondary endpoints of clinical trials of approved agents in NSCLC are summarized in Table [1](#onco12104-tbl-0001){ref-type="table"}.

Clinical Trials with OS as the Primary Endpoint {#onco12104-sec-0004}
-----------------------------------------------

The gold standard primary endpoint for clinical trials in oncology has been OS, as it is not subject to investigator bias, it guides clinical practice decisions based on the potential risks and benefits of a particular therapy, and it is the clinical endpoint in which patients are most interested \[[12](#onco12104-bib-0012){ref-type="ref"}\]. However, disadvantages of using OS as an endpoint have been noted, including the risk of confounding due to second‐line treatments or treatment crossovers and the length of time required for completion of trials, highlighting the need for alternative endpoints in certain contexts \[[12](#onco12104-bib-0012){ref-type="ref"}\], \[[13](#onco12104-bib-0013){ref-type="ref"}\].

In the trial that led to approval of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib (Tarceva, Genentech/Roche; South San Francisco, CA, <https://www.gene.com>/) for NSCLC in patients who previously received chemotherapy (BR.21), the primary endpoint was OS, with PFS, objective response, duration of response (DoR), toxic effects, and quality of life (QoL) designated as secondary endpoints \[[14](#onco12104-bib-0014){ref-type="ref"}\]. Results from this trial revealed that erlotinib was associated with OS, PFS, and objective response rate (ORR) benefits in this specific patient population; subsequent studies demonstrated that erlotinib was associated with worse outcomes for patients with *EGFR* wild‐type tumors \[[15](#onco12104-bib-0015){ref-type="ref"}\].

Afatinib (Gilotrif, Boehringer Ingelheim; Ingelheim, Germany, <https://www.boehringer-ingelheim.com>/) is an irreversible ErbB family blocker of EGFR, erb‐b2 receptor tyrosine kinase 2 (ErbB2), and ErbB4 \[16, 17\], with in vitro activity against ErbB3 phosphorylation \[[18](#onco12104-bib-0018){ref-type="ref"}\]. Patients with advanced, metastatic NSCLC who failed previous treatment with EGFR TKIs were randomly assigned to receive afatinib or placebo in the LUX‐Lung 1 trial, which examined OS as the primary endpoint; secondary endpoints included PFS, objective response, response duration, safety, and health‐related QoL \[[19](#onco12104-bib-0019){ref-type="ref"}\]. While no improvements in OS were noted for afatinib versus placebo, a robust PFS benefit was observed for afatinib compared with placebo in the overall pretreated population as well as in patients whose tumors harbored *EGFR* mutations.

The antiangiogenic vascular endothelial growth factor receptor (VEGFR) inhibitor bevacizumab (Avastin, Genentech/Roche) was evaluated in patients with advanced nonsquamous NSCLC following randomization into treatment groups consisting of either paclitaxel/carboplatin alone or with bevacizumab in the pivotal ECOG 4599 trial \[[20](#onco12104-bib-0020){ref-type="ref"}\]. The primary endpoint of improved OS was achieved with the addition of bevacizumab to chemotherapy. Similarly, the secondary endpoints of PFS and ORR were also improved with the addition of bevacizumab to standard chemotherapy.

More recently, a phase III study evaluated ramucirumab (Cyramza, Eli Lilly and Company; Indianapolis, IN, <https://www.lilly.com>/), a monoclonal antibody that targets VEGFR‐2, in combination with docetaxel as second‐line treatment for stage IV NSCLC after platinum‐based therapy (REVEL) \[[21](#onco12104-bib-0021){ref-type="ref"}\]. Significant OS (primary endpoint), PFS, and ORR improvements were observed with ramucirumab/docetaxel compared with placebo/docetaxel. Based on these positive findings, the FDA approved ramucirumab in combination with docetaxel for this indication in December 2014.

In November 2015, the FDA approved the anti‐EGFR monoclonal antibody necitumumab (Portrazza, Eli Lilly and Company) in combination with gemcitabine and cisplatin for the first‐line treatment of patients with advanced squamous NSCLC. This approval was based on the results of the open‐label, randomized SQUIRE trial comparing gemcitabine plus cisplatin with or without necitumumab. Results from the SQUIRE trial demonstrated significant improvements in OS (primary endpoint) and PFS but no improvement in ORR when necitumumab was added to gemcitabine/cisplatin chemotherapy \[[22](#onco12104-bib-0022){ref-type="ref"}\].

Clinical Trials with PFS or Time to Progression as the Primary Endpoint {#onco12104-sec-0005}
-----------------------------------------------------------------------

Recent trends in oncology clinical trials have shifted toward choosing surrogates such as PFS as the primary endpoint. While OS may be easier to examine in later‐line studies, when there may be less influence from subsequent therapies, there are several advantages to measuring PFS in clinical trials. These include shortened trial duration and faster time to drug approval \[[12](#onco12104-bib-0012){ref-type="ref"}\]. Moreover, PFS can provide a clearer picture of the activity of an agent and allows for assessment of the duration of tumor control and measurement of tumor shrinkage and tumor stabilization, both of which are effects associated with most recently developed targeted agents \[[23](#onco12104-bib-0023){ref-type="ref"}\]. On the other hand, disadvantages include the need for frequent and ongoing assessment of disease status, variable definitions regarding progression, and risk of bias \[[23](#onco12104-bib-0023){ref-type="ref"}\], \[[24](#onco12104-bib-0024){ref-type="ref"}\]. With respect to clinical trials for NSCLC, the Oncologic Drugs Advisory Committee recommended PFS as an endpoint for advanced NSCLC clinical trials in 2003 \[12\], but whether PFS can be used as a valid surrogate endpoint remains controversial \[[23](#onco12104-bib-0023){ref-type="ref"}\], \[[25](#onco12104-bib-0025){ref-type="ref"}\], \[[26](#onco12104-bib-0026){ref-type="ref"}\]. "PFS can provide a clearer picture of the activity of an agent and allows for assessment of the duration of tumor control and measurement of tumor shrinkage and tumor stabilization, both of which are effects associated with most recently developed targeted agents."

In contrast to the design of BR.21, PFS was selected as the primary endpoint in subsequent trials that led to the approval of erlotinib for maintenance treatment in advanced NSCLC (SATURN) \[[27](#onco12104-bib-0027){ref-type="ref"}\] as well as first‐line treatment for patients with NSCLC harboring *EGFR* mutations (EURTAC) \[[28](#onco12104-bib-0028){ref-type="ref"}\]. As a secondary endpoint in both of these trials, OS was prolonged with erlotinib versus placebo in the maintenance setting \[[27](#onco12104-bib-0027){ref-type="ref"}\], but no OS benefit was observed with erlotinib compared with chemotherapy in patients with *EGFR* mutations, likely due to subsequent therapies \[[28](#onco12104-bib-0028){ref-type="ref"}\], \[[29](#onco12104-bib-0029){ref-type="ref"}\]. More specifically, subgroup analyses revealed no OS benefit with erlotinib for patients with del19 or L858R *EGFR* mutations \[[29](#onco12104-bib-0029){ref-type="ref"}\]. Although improvements in PFS were noted in both trials, OS was designated as the regulatory endpoint for approval of erlotinib in maintenance treatment of advanced NSCLC.

In the LUX‐Lung 3 trial, patients with advanced nonsquamous NSCLC harboring *EGFR* mutations were stratified and assigned 2:1 to afatinib or cisplatin/pemetrexed \[[6](#onco12104-bib-0006){ref-type="ref"}\]. The trial met its primary endpoint of PFS but failed to demonstrate an improvement in OS following treatment with afatinib. Nevertheless, the robust PFS benefit associated with afatinib in this trial led to its approval by the FDA for first‐line treatment of advanced NSCLC in patients harboring sensitizing *EGFR* mutations \[[30](#onco12104-bib-0030){ref-type="ref"}\]. The LUX‐Lung 6 trial was a similarly designed trial comparing afatinib versus cisplatin/gemcitabine as first‐line treatment in Asian patients with advanced NSCLC harboring *EGFR* mutations \[[31](#onco12104-bib-0031){ref-type="ref"}\]. Similar to the results from LUX‐Lung 3, a PFS but not OS benefit was observed in the overall population. Interestingly, a prespecified subgroup analysis of patients with del19 *EGFR* mutations indicated that afatinib prolonged OS compared with chemotherapy in both LUX‐Lung 3 and LUX‐Lung 6 \[32\]. The LUX‐Lung 8 trial compared afatinib versus erlotinib as second‐line treatment in patients with advanced squamous cell carcinoma of the lung \[[33](#onco12104-bib-0033){ref-type="ref"}\]. At a median follow‐up of 18.4 months, PFS (primary endpoint) and OS (key secondary endpoint) were significantly greater in the afatinib group than in the erlotinib group. This PFS benefit (2.6 months with afatinib versus 1.9 months with erlotinib; hazard ratio, 0.81) led to the FDA approval of afatinib for the treatment of patients with metastatic, squamous NSCLC progressing after platinum‐based therapy \[[30](#onco12104-bib-0030){ref-type="ref"}\].

FDA approval for crizotinib (Xalkori, Pfizer; New London, CT, <http://www.pfizer.com>/), an inhibitor that targets the echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) fusion product, was based on the results of a phase III trial in which patients with locally advanced or metastatic *ALK*‐rearranged NSCLC who had received one prior platinum‐based regimen were treated with either crizotinib or chemotherapy (pemetrexed or docetaxel) \[[7](#onco12104-bib-0007){ref-type="ref"}\]. A significant PFS benefit (the primary endpoint) along with increased ORR was associated with crizotinib versus chemotherapy, but no improvement in OS, a secondary endpoint, was observed.

Similar to the ECOG 4599 trial, the AVAiL placebo‐controlled phase III trial evaluated bevacizumab at 7.5‐mg/kg and 15‐mg/kg doses in combination with cisplatin/gemcitabine for first‐line treatment of advanced NSCLC \[[34](#onco12104-bib-0034){ref-type="ref"}\]. The primary endpoint was amended from OS to PFS, and while a significant improvement in PFS was observed with bevacizumab, the secondary endpoint of improved OS was not met with this agent at either dose \[[35](#onco12104-bib-0035){ref-type="ref"}\].

Clinical Trials with Objective Response as the Primary Endpoint {#onco12104-sec-0006}
---------------------------------------------------------------

Objective response is often assessed by Response Evaluation Criteria in Solid Tumors (RECIST) and looks at both the complete response and partial response to therapy \[[12](#onco12104-bib-0012){ref-type="ref"}\]. Advantages associated with using objective response in clinical trials include the ability to measure efficacy in single‐arm studies and the ability of investigators to attribute the effect to the drug and not to the natural history of the patient \[[12](#onco12104-bib-0012){ref-type="ref"}\]. Objective response has also been proposed to be a more informative endpoint for discovering predictive biomarkers compared with OS \[[36](#onco12104-bib-0036){ref-type="ref"}\]. On the other hand, objective response may not be able to capture the full long‐term benefits of treatment, and additional endpoints may be needed to validate the clinical benefit \[[12](#onco12104-bib-0012){ref-type="ref"}\], \[[37](#onco12104-bib-0037){ref-type="ref"}\].

Ongoing and completed phase I and II trials evaluating crizotinib in NSCLC have designated objective response as the primary endpoint \[[38](#onco12104-bib-0038){ref-type="ref"}\], \[[39](#onco12104-bib-0039){ref-type="ref"}\]. Significant improvements in ORR were observed in two single‐arm trials of crizotinib for locally advanced or metastatic *ALK*‐rearranged NSCLC, which contributed to the accelerated approval of crizotinib for this indication \[[9](#onco12104-bib-0009){ref-type="ref"}\], \[[38](#onco12104-bib-0038){ref-type="ref"}\], \[[39](#onco12104-bib-0039){ref-type="ref"}\]. More recently, high response rates were noted in a completed phase I study for ceritinib (Zykadia, Novartis Pharmaceuticals; East Hanover, NJ, <https://www.pharma.us.novartis.com>/) in a similar patient population, including those who progressed after receiving crizotinib \[[40](#onco12104-bib-0040){ref-type="ref"}\]. The high ORR observed with ceritinib led to FDA approval for this agent in patients with *ALK*‐rearranged NSCLC \[[41](#onco12104-bib-0041){ref-type="ref"}\]. Another ALK inhibitor, alectinib (Alecensa, Genentech), was subsequently granted accelerated approval by the FDA in late 2015 for treatment of patients with *ALK*‐positive, metastatic NSCLC who have progressed on or are intolerant to crizotinib \[[42](#onco12104-bib-0042){ref-type="ref"}\]. This approval was based on the high ORR (primary endpoint) of 50% and 48% observed in two pivotal single‐arm studies \[[43](#onco12104-bib-0043){ref-type="ref"}\], \[[44](#onco12104-bib-0044){ref-type="ref"}\].

Most recently, the FDA approved the mutant‐selective EGFR inhibitor osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP; Wilmington, DE, <https://www.astrazeneca-us.com>/) for the treatment of patients with advanced or metastatic NSCLC harboring T790M‐mutant *EGFR* who have progressed on EGFR‐TKI therapy. The approval was based on initial results from the AURA trial program evaluating the safety and efficacy of osimertinib (AZD9291) in NSCLC patients who progressed on EGFR‐TKI therapy. Primary endpoints of the phase I AURA study included safety, tolerability, and efficacy as measured by ORR, with secondary endpoints including DoR and PFS. Results from AURA demonstrated promising response rates in NSCLC patients harboring T790M *EGFR* mutations \[[45](#onco12104-bib-0045){ref-type="ref"}\], \[[46](#onco12104-bib-0046){ref-type="ref"}\], \[[47](#onco12104-bib-0047){ref-type="ref"}\]. Due to the accelerated approval of osimertinib, additional studies are ongoing to validate its efficacy. These include phase III studies of first‐line osimertinib versus gefitinib or erlotinib in advanced, *EGFR* mutation‐positive NSCLC (FLAURA; [ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT02296125) and osimertinib versus platinum‐based chemotherapy in advanced, T790M mutation‐positive NSCLC after progression on EGFR‐TKI therapy (AURA3; NCT02151981). PFS is the designated primary endpoint for both phase III trials, with OS and ORR among several secondary endpoints specified for both trials.

Recent Immunotherapy Approvals in NSCLC {#onco12104-sec-0007}
=======================================

Based on promising efficacy data, the FDA approved the immunotherapeutic agents nivolumab and pembrolizumab for NSCLC treatment in 2015. Nivolumab (Opdivo, Bristol‐Myers Squibb; Princeton, NJ, <http://www.bms.com>), a human anti‐programmed death‐1 antibody, gained approval in March 2015 for patients with advanced or metastatic squamous NSCLC following platinum‐based chemotherapy. Approval for this indication was based on the CheckMate 017 and CheckMate 063 trials demonstrating efficacy and safety of nivolumab. In the CheckMate 017 trial, nivolumab showed significant improvement in OS, the primary endpoint, compared with docetaxel \[[48](#onco12104-bib-0048){ref-type="ref"}\]. Significant improvements in ORR and PFS were also observed with nivolumab compared with docetaxel for squamous NSCLC in this trial. The CheckMate 063 single‐arm trial specified objective response as the primary endpoint. Results from this trial demonstrated clinically meaningful antitumor activity for nivolumab along with a tolerable safety profile \[[11](#onco12104-bib-0011){ref-type="ref"}\]. In October 2015, nivolumab was granted FDA approval for the treatment of advanced nonsquamous NSCLC with progression on or after platinum therapy based on data from the CheckMate 057 trial. The primary endpoint of this trial was OS, which, along with response rate, was significantly improved with nivolumab versus docetaxel, and levels of tumor programmed death‐ligand 1 (PD‐L1) expression were positively associated with clinical benefit \[[49](#onco12104-bib-0049){ref-type="ref"}\]. Although nivolumab treatment did not improve PFS compared with docetaxel, the rate of PFS at 1 year was higher with nivolumab \[[49](#onco12104-bib-0049){ref-type="ref"}\].

Pembrolizumab (Keytruda, Merck & Company; Whitehouse Station, NJ, <http://www.merck.com>) was approved in October 2015 for the treatment of advanced or metastatic NSCLC with expression of the immune checkpoint protein PD‐L1 as determined by an FDA‐approved test. The single‐arm phase I trial (KEYNOTE‐001) leading to FDA approval of pembrolizumab had primary objectives of evaluating safety, side effect profile, and response rate. Results from KEYNOTE‐001 demonstrated efficacy of pembrolizumab and an acceptable side effect profile in advanced NSCLC patients \[[10](#onco12104-bib-0010){ref-type="ref"}\]. The efficacy of pembrolizumab was improved in patients whose tumors expressed PD‐L1 in at least 50% of the tumor cells, supporting the predictive value of PD‐L1 expression in response to pembrolizumab \[[10](#onco12104-bib-0010){ref-type="ref"}\]. Ongoing phase III trials of pembrolizumab have designated a variety of primary endpoints to validate its efficacy in NSCLC, including disease‐free survival (DFS), PFS, and OS (NCT02504372, NCT02578680, NCT02220894, NCT02142738, and NCT01905657).

Correlative Analysis of Clinical Trial Endpoints Supporting FDA Approval {#onco12104-sec-0008}
------------------------------------------------------------------------

Since 1990, 19 randomized controlled clinical trials have been identified that supported FDA approval of nontargeted and targeted agents for NSCLC \[[6](#onco12104-bib-0006){ref-type="ref"}\], \[[7](#onco12104-bib-0007){ref-type="ref"}\], \[[14](#onco12104-bib-0014){ref-type="ref"}\], \[[20](#onco12104-bib-0020){ref-type="ref"}\], \[[21](#onco12104-bib-0021){ref-type="ref"}\], \[[22](#onco12104-bib-0022){ref-type="ref"}\], \[[27](#onco12104-bib-0027){ref-type="ref"}\], \[[28](#onco12104-bib-0028){ref-type="ref"}\], \[[31](#onco12104-bib-0031){ref-type="ref"}\], \[[33](#onco12104-bib-0033){ref-type="ref"}\], \[[48](#onco12104-bib-0048){ref-type="ref"}\], \[[49](#onco12104-bib-0049){ref-type="ref"}\], \[[50](#onco12104-bib-0050){ref-type="ref"}\], \[[51](#onco12104-bib-0051){ref-type="ref"}\], \[[52](#onco12104-bib-0052){ref-type="ref"}\], \[[53](#onco12104-bib-0053){ref-type="ref"}\], \[[54](#onco12104-bib-0054){ref-type="ref"}\], \[[55](#onco12104-bib-0055){ref-type="ref"}\], \[[56](#onco12104-bib-0056){ref-type="ref"}\]. Among the 18 trials that reported both OS and PFS endpoints (one trial reported only OS and ORR \[[51](#onco12104-bib-0051){ref-type="ref"}\]), only nine trials reported improvements in both OS and PFS with the investigational agent (Table [2](#onco12104-tbl-0002){ref-type="table"}); among the remaining trials that did not achieve both endpoints, six trials reported improvements in only PFS, and three trials reported an improvement in only OS. Likewise, among 19 trials that reported both OS and objective response endpoints, 11 trials reported improvements in both OS and objective response with the investigational agent, and six trials reported improvements in only objective response with the investigational agent. It is worth noting that several of the trials that demonstrated PFS but not OS benefits reported crossover of patients between treatment arms \[[6](#onco12104-bib-0006){ref-type="ref"}\], \[[7](#onco12104-bib-0007){ref-type="ref"}\], \[[28](#onco12104-bib-0028){ref-type="ref"}\]. Additionally, while the individual LUX‐Lung 3 and LUX‐Lung 6 trials demonstrated improvements only in PFS with afatinib in the overall population, a prespecified analysis of patients with del19 *EGFR* mutations demonstrated an OS benefit with afatinib versus chemotherapy in both trials \[[32](#onco12104-bib-0032){ref-type="ref"}\], illustrating the utility of well‐defined molecular biomarkers in determining outcomes in clinical trials. Similarly, while median PFS did not favor nivolumab over docetaxel in nonsquamous NSCLC, the rates of PFS and OS at 1 year were higher with nivolumab in this trial \[[49](#onco12104-bib-0049){ref-type="ref"}\]. Patients with higher expression of PD‐L1 at predefined levels demonstrated improved PFS with nivolumab compared with docetaxel, further highlighting the importance of biomarkers of response in NSCLC.

Discussion and Clinical Perspectives {#onco12104-sec-0009}
====================================

Historically, clinical trials for NSCLC have relied on improved OS as the primary endpoint for regulatory submission and approval of investigational agents. However, FDA approvals for afatinib, crizotinib, ceritinib, osimertinib, nivolumab, and pembrolizumab for the treatment of specific patient populations with advanced NSCLC in 2013 to 2015 have highlighted increases in the use of appropriate surrogate endpoints in establishing the clinical benefit of investigational agents. These shifts to include surrogate endpoints may be influenced by the increasing number of targeted agents in clinical development.

In particular, PFS has become a widely used surrogate endpoint in many oncology clinical trials, including trials for NSCLC, due to the shorter follow‐up required as well as the lack of crossover effects or confounding in patients receiving multiple lines of therapy \[[12](#onco12104-bib-0012){ref-type="ref"}\]. Discussion around this trend toward designation of PFS as the primary endpoint for NSCLC trials is increasing, and clinicians and investigators are considering its utilization in NSCLC trial design \[[23](#onco12104-bib-0023){ref-type="ref"}\], \[[25](#onco12104-bib-0025){ref-type="ref"}\], \[[57](#onco12104-bib-0057){ref-type="ref"}\]. In support of this viewpoint, a meta‐analysis of 60 randomized NSCLC trials demonstrated that PFS is a valid surrogate endpoint for OS in studies evaluating chemotherapy and radiotherapy in patients with locally advanced lung cancers \[[58](#onco12104-bib-0058){ref-type="ref"}\]. Another meta‐analysis of phase II trials for advanced NSCLC revealed that failure‐free survival or PFS at 12 weeks is a strong predictor of subsequent patient survival \[[59](#onco12104-bib-0059){ref-type="ref"}\]. Furthermore, an analysis of 14 randomized controlled trials in NSCLC showed a strong correlation between ORR and PFS, but an association between ORR and OS or between PFS and OS could not be established, possibly because of crossover or longer OS with targeted therapies \[[60](#onco12104-bib-0060){ref-type="ref"}\]. Analyses of these trials at the patient level demonstrated that responders had more favorable PFS and OS compared with nonresponders, thereby further strengthening the argument for using ORR and PFS as primary endpoints for approval \[[60](#onco12104-bib-0060){ref-type="ref"}\].

The investigational drug and its mechanism of action should be considered when deciding on clinical trial endpoints. Immunotherapeutic agents such as nivolumab and pembrolizumab are often associated with delayed response kinetics, potentially due to the time needed for immune cell expansion and invasion into the tumor \[[61](#onco12104-bib-0061){ref-type="ref"}\]. These kinetics may complicate the assessment of response, when tumor growth, normally characterized as disease progression, may occur before the onset of response \[[61](#onco12104-bib-0061){ref-type="ref"}\], \[[62](#onco12104-bib-0062){ref-type="ref"}\]. In an effort to capture the differences in response kinetics and sequence often seen with immunotherapies, new response criteria were proposed to allow for immunotherapy‐specific assessment of patient response \[[62](#onco12104-bib-0062){ref-type="ref"}\]. The role of these immune‐related response criteria in clinical trial design and interpretation is unclear, as the trials leading to approval of nivolumab and pembrolizumab in NSCLC primarily used RECIST criteria for assessment of response \[[10](#onco12104-bib-0010){ref-type="ref"}\], \[[11](#onco12104-bib-0011){ref-type="ref"}\], \[[48](#onco12104-bib-0048){ref-type="ref"}\], \[[49](#onco12104-bib-0049){ref-type="ref"}\]. The trials comparing nivolumab with docetaxel in squamous and nonsquamous NSCLC also designated OS as the primary endpoint \[[48](#onco12104-bib-0048){ref-type="ref"}\], \[[49](#onco12104-bib-0049){ref-type="ref"}\], suggesting that the effects of immune‐mediated responses on choosing trial endpoints are not well understood. As we learn more about these agents, new trial designs and endpoints are likely to be adopted to truly assess the clinical benefit of these drugs. "Immunotherapeutic agents such as nivolumab and pembrolizumab are often associated with delayed response kinetics, potentially due to the time needed for immune cell expansion and invasion into the tumor. These kinetics may complicate the assessment of response, when tumor growth, normally characterized as disease progression, may occur before the onset of response."

Endpoint choice can also vary based on the clinical development strategy. Traditional approvals of targeted agents in NSCLC, such as erlotinib and afatinib, were based on time‐to‐event endpoints (e.g., OS, DFS, or PFS), which can lengthen the approval process. Recent accelerated drug approvals in NSCLC (e.g., osimertinib) have instead been based on ORR and/or DoR in single‐arm studies. This allows agents with promising efficacy to be utilized more rapidly, with the expectation that confirmatory randomized controlled trials measuring a time‐to‐event endpoint will follow. This strategy is supported by recent results showing correlation between response rates and PFS \[[60](#onco12104-bib-0060){ref-type="ref"}\]. Thus, surrogate endpoints can predict clinical benefit and may allow more rapid drug approval to improve the treatment of NSCLC.

While the correlative analysis of clinical trial endpoints for FDA‐approved agents revealed some discordance between OS and PFS benefits in approximately half of the clinical trials that were reviewed, effects of crossover and subsequent lines of therapy on OS must be taken into consideration. Consequently, evaluation of individual OS and PFS data for each patient with respect to their treatment history would likely provide valuable information regarding the validity of PFS as a surrogate endpoint for NSCLC clinical trials. Additionally, the role of alternate endpoints such as PFS in demonstrating clinical benefit will likely be impacted by patient selection. The triple angiokinase inhibitor nintedanib (Vargatef, Boehringer Ingelheim) was approved by the European Medicines Agency in combination with docetaxel for the treatment of locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma histology after first‐line chemotherapy. This approval was based on results of the LUME‐Lung 1 trial, which demonstrated a significant improvement in PFS (primary endpoint) with nintedanib in patients with advanced NSCLC of all histologies \[[63](#onco12104-bib-0063){ref-type="ref"}\]. An overall survival benefit was seen only in NSCLC patients with adenocarcinoma, illustrating the potential impact of patient selection on the correlation between trial endpoints. Importantly, the approval of nintedanib in the European Union also indicates that regulatory agencies may differ in their acceptance of surrogate trial endpoints.

While many of the recent clinical trials for NSCLC have designated PFS as the primary endpoint, the topic remains controversial, and several investigators have questioned the validity of PFS as a surrogate endpoint for OS in NSCLC, especially in settings in which the magnitude of PFS benefit is small \[[26](#onco12104-bib-0026){ref-type="ref"}\]. To address some of the concerns surrounding the use of PFS as an endpoint, the FDA has recommended the inclusion of sensitivity analyses in the design of clinical trials to evaluate the robustness of PFS as an endpoint in phase III trials and to determine the likelihood of the results being oversimplified \[[23](#onco12104-bib-0023){ref-type="ref"}\], \[[64](#onco12104-bib-0064){ref-type="ref"}\]. Additionally, clinical studies could be designed with coprimary endpoints such as OS and PFS, thus allowing faster assessments of response while having adequate power to show OS benefit.

Conclusion {#onco12104-sec-0010}
==========

The use of surrogate endpoints in clinical trials for NSCLC allows investigators to obtain information regarding the efficacy of an investigational agent that OS by itself cannot provide, and these endpoints should be valid for approval where appropriate. However, clear guidance on the use of these endpoints should be implemented, as currently no specific guidelines have been established regarding the use of PFS or objective response as the primary endpoint. Clinical trials for both afatinib and crizotinib in patients with NSCLC demonstrate examples in which robust PFS benefits have led to recent FDA approvals and highlight increasing regulatory acceptance of PFS as a surrogate endpoint in clinical trials for NSCLC. Careful planning and inclusion of appropriate endpoints and analyses with respect to the type of investigational agent and the patient population being evaluated will help ensure that clinical benefit of future investigational agents is properly assessed.
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